Kolexia
Alt Marie Oncologie médicale
Alt Marie
Oncologie médicale
Centre Hospitalier de Haguenau
Haguenau, France
54 Activités
91 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Carcinome épidermoïde de la tête et du cou Tumeurs de la tête et du cou Métastase tumorale Néphrocarcinome Tumeurs du sein Tumeurs du rein Cellules tumorales circulantes

Collaborateurs

Voir plus
Le Tourneau Christophe
Le Tourneau Christophe
Clcc Institut Curie, Paris, France
Sablin Marie-Paule
Sablin Marie-Paule
Clcc Institut Curie, Paris, France
Loirat Delphine
Loirat Delphine
Clcc Institut Curie, Paris, France
Vessaud Julie
Vessaud Julie
Centre Hospitalier de Haguenau, Haguenau, France

Industries

Voir plus
VIATRIS MEDICAL
6 collaboration(s)
Dernière en 2023
Mylan Medical
4 collaboration(s)
Dernière en 2021
Lilly
2 collaboration(s)
Dernière en 2023
Amgen
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
BMC cancer   29 septembre 2023
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC).
Seminars in oncology   08 septembre 2022
286P Outcome of patients with HER2-positive brain metastatic breast cancer: A 10-year retrospective study
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
319P A propensity score weighted study comparing two versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Investigational new drugs   28 juillet 2021
COPAN-ORL06: Phase ib/II Trial of Copanlisib, a Selective PI3K Inhibitor, in Combination With Cetuximab in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss.
Essai Clinique (Unicancer)   24 mars 2021
Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature.
Oncology and therapy   16 janvier 2021
Enfortumab Vedotin in urothelial cancer.
Therapeutic advances in urology   27 décembre 2020
Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials.
Personalized medicine   20 novembre 2019